{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:43:37Z","timestamp":1761745417578,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emergence of novel doping agents is a continuous issue for analysts who aim to maintain the integrity of horseracing together with the well\u2010being and safety of the animals and riders involved. Untargeted mass spectrometric analysis presents a potential improvement for antidoping as it enables the detection of compounds being indirectly affected by an administered drug. In this study, liquid chromatography\u2013high\u2010resolution mass spectrometry was used to investigate a 12\u2010horse administration study of the synthetic opioid, butorphanol. A mass spectrometric workflow capable of detecting metabolic differences for an extended period of time was successfully developed. This proof\u2010of\u2010concept study demonstrates the potential of untargeted workflows to provide a list of biomarkers of exposure and effect that are indicative of drug administration which may be implemented into routine testing for improved doping control.<\/jats:p>","DOI":"10.1002\/dta.3021","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T06:13:49Z","timestamp":1614233629000},"page":"1001-1007","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Towards an untargeted mass spectrometric approach for improved screening in equine antidoping"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1955-2951","authenticated-orcid":false,"given":"Bethany","family":"Keen","sequence":"first","affiliation":[{"name":"Centre for Forensic Science University of Technology Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8617","authenticated-orcid":false,"given":"Adam","family":"Cawley","sequence":"additional","affiliation":[{"name":"Australian Racing Forensic Laboratory Racing NSW  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Fouracre","sequence":"additional","affiliation":[{"name":"Agilent Technologies  Mulgrave Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Pyke","sequence":"additional","affiliation":[{"name":"Agilent Technologies  Santa Clara California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-3612","authenticated-orcid":false,"given":"Shanlin","family":"Fu","sequence":"additional","affiliation":[{"name":"Centre for Forensic Science University of Technology Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(95)03268-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2009.06.859"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.09.87"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2788"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mas.20108"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5b03165"},{"key":"e_1_2_7_8_1","unstructured":"Authorities IFOH.International agreement on breeding racing and wagering. France: International Federation Of Horseracing Authorities;2018:110."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2180"},{"key":"e_1_2_7_10_1","first-page":"199","volume-title":"Drugs and the Performance Horse","author":"Tobin T","year":"1981"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(85)90065-1"},{"key":"e_1_2_7_12_1","first-page":"186","article-title":"Butorphanol levels in the plasma and urine of the horse following intramuscular injection","author":"Beaumier P","year":"1983","journal-title":"Control of the Use of Drugs in Racehorses"},{"issue":"3","key":"e_1_2_7_13_1","first-page":"394","article-title":"Morphine: a double\u2010blind comparison of their parenteral analgesic activity","volume":"55","author":"Tavakoli M","year":"1976","journal-title":"Anesthesia & Analgesia"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600690211"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197816060-00001"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.12265"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00473-8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2019.02.010"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2012.01385.x"},{"issue":"2","key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2460\/ajvr.1984.45.02.211","article-title":"Analgesic effects of butorphanol in horses: dose\u2010response studies","volume":"45","author":"Kalpravidh M","year":"1984","journal-title":"Am J Vet Res"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2006.05.021"},{"first-page":"1","volume-title":"Agilent Mass Profiler Professional operation for chemometric analysis","year":"2019","key":"e_1_2_7_22_1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12838"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2008.01004.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.174"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.3021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:13:32Z","timestamp":1760386412000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/dta.3021"],"URL":"https:\/\/doi.org\/10.1002\/dta.3021","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"type":"print","value":"1942-7603"},{"type":"electronic","value":"1942-7611"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}